经颅磁刺激疗法是否应被视为成人重度抑郁发作的一线治疗方法?

IF 3.7 3区 医学 Q1 CLINICAL NEUROLOGY Clinical Neurophysiology Pub Date : 2024-06-19 DOI:10.1016/j.clinph.2024.06.004
Sean J. O’Sullivan , Derrick M. Buchanan , Jean-Marie V. Batail , Nolan R. Williams
{"title":"经颅磁刺激疗法是否应被视为成人重度抑郁发作的一线治疗方法?","authors":"Sean J. O’Sullivan ,&nbsp;Derrick M. Buchanan ,&nbsp;Jean-Marie V. Batail ,&nbsp;Nolan R. Williams","doi":"10.1016/j.clinph.2024.06.004","DOIUrl":null,"url":null,"abstract":"<div><p>Treatment-resistant depression (TRD) is an epidemic with rising social, economic, and political costs. In a patient whose major depressive episode (MDE) persists through an adequate antidepressant trial, insurance companies often cover alternative treatments which may include repetitive transcranial magnetic stimulation (rTMS). RTMS is an FDA-cleared neuromodulation technique for TRD which is safe, efficacious, noninvasive, and well-tolerated. Recent developments in the optimization of rTMS algorithms and targeting have increased the efficacy of rTMS in treating depression, improved the clinical convenience of these treatments, and decreased the cost of a course of rTMS. In this opinion paper, we make a case for why conventional FDA-cleared rTMS should be considered as a first-line treatment for all adult MDEs. RTMS is compared to other first-line treatments including psychotherapy and SSRIs. These observations suggest that rTMS has similar efficacy, fewer side-effects, lower risk of serious adverse events, comparable compliance, the potential for more rapid relief, and cost-effectiveness. This suggestion, however, would be strengthened by further research with an emphasis on treatment-naive subjects in their first depressive episode, and trials directly contrasting rTMS with SSRIs or psychotherapy.</p></div>","PeriodicalId":10671,"journal":{"name":"Clinical Neurophysiology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Should rTMS be considered a first-line treatment for major depressive episodes in adults?\",\"authors\":\"Sean J. O’Sullivan ,&nbsp;Derrick M. Buchanan ,&nbsp;Jean-Marie V. Batail ,&nbsp;Nolan R. Williams\",\"doi\":\"10.1016/j.clinph.2024.06.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Treatment-resistant depression (TRD) is an epidemic with rising social, economic, and political costs. In a patient whose major depressive episode (MDE) persists through an adequate antidepressant trial, insurance companies often cover alternative treatments which may include repetitive transcranial magnetic stimulation (rTMS). RTMS is an FDA-cleared neuromodulation technique for TRD which is safe, efficacious, noninvasive, and well-tolerated. Recent developments in the optimization of rTMS algorithms and targeting have increased the efficacy of rTMS in treating depression, improved the clinical convenience of these treatments, and decreased the cost of a course of rTMS. In this opinion paper, we make a case for why conventional FDA-cleared rTMS should be considered as a first-line treatment for all adult MDEs. RTMS is compared to other first-line treatments including psychotherapy and SSRIs. These observations suggest that rTMS has similar efficacy, fewer side-effects, lower risk of serious adverse events, comparable compliance, the potential for more rapid relief, and cost-effectiveness. This suggestion, however, would be strengthened by further research with an emphasis on treatment-naive subjects in their first depressive episode, and trials directly contrasting rTMS with SSRIs or psychotherapy.</p></div>\",\"PeriodicalId\":10671,\"journal\":{\"name\":\"Clinical Neurophysiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Neurophysiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1388245724001780\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurophysiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1388245724001780","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

难治性抑郁症(TRD)是一种流行病,其社会、经济和政治成本不断上升。如果重度抑郁发作(MDE)患者经过充分的抗抑郁试验后仍无法治愈,保险公司通常会支付替代治疗费用,其中可能包括重复经颅磁刺激(rTMS)。经颅磁刺激(RTMS)是一种经美国食品及药物管理局(FDA)批准的治疗 TRD 的神经调节技术,具有安全、有效、无创、耐受性好等特点。最近,经颅磁刺激算法和靶向性的优化发展提高了经颅磁刺激治疗抑郁症的疗效,改善了这些治疗的临床便利性,并降低了经颅磁刺激疗程的成本。在这篇论文中,我们论证了为什么常规经 FDA 批准的经颅磁刺激疗法应被视为所有成人 MDE 的一线治疗方法。我们将经颅磁刺激疗法与其他一线疗法(包括心理疗法和 SSRIs)进行了比较。这些观察结果表明,经颅磁刺激具有相似的疗效、较少的副作用、较低的严重不良事件风险、可比的依从性、更快缓解的潜力以及成本效益。不过,如果能进一步研究首次抑郁发作时未接受过治疗的受试者,并将经颅磁刺激疗法与 SSRIs 或心理疗法进行直接对比试验,这一建议将会得到进一步加强。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Should rTMS be considered a first-line treatment for major depressive episodes in adults?

Treatment-resistant depression (TRD) is an epidemic with rising social, economic, and political costs. In a patient whose major depressive episode (MDE) persists through an adequate antidepressant trial, insurance companies often cover alternative treatments which may include repetitive transcranial magnetic stimulation (rTMS). RTMS is an FDA-cleared neuromodulation technique for TRD which is safe, efficacious, noninvasive, and well-tolerated. Recent developments in the optimization of rTMS algorithms and targeting have increased the efficacy of rTMS in treating depression, improved the clinical convenience of these treatments, and decreased the cost of a course of rTMS. In this opinion paper, we make a case for why conventional FDA-cleared rTMS should be considered as a first-line treatment for all adult MDEs. RTMS is compared to other first-line treatments including psychotherapy and SSRIs. These observations suggest that rTMS has similar efficacy, fewer side-effects, lower risk of serious adverse events, comparable compliance, the potential for more rapid relief, and cost-effectiveness. This suggestion, however, would be strengthened by further research with an emphasis on treatment-naive subjects in their first depressive episode, and trials directly contrasting rTMS with SSRIs or psychotherapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Neurophysiology
Clinical Neurophysiology 医学-临床神经学
CiteScore
8.70
自引率
6.40%
发文量
932
审稿时长
59 days
期刊介绍: As of January 1999, The journal Electroencephalography and Clinical Neurophysiology, and its two sections Electromyography and Motor Control and Evoked Potentials have amalgamated to become this journal - Clinical Neurophysiology. Clinical Neurophysiology is the official journal of the International Federation of Clinical Neurophysiology, the Brazilian Society of Clinical Neurophysiology, the Czech Society of Clinical Neurophysiology, the Italian Clinical Neurophysiology Society and the International Society of Intraoperative Neurophysiology.The journal is dedicated to fostering research and disseminating information on all aspects of both normal and abnormal functioning of the nervous system. The key aim of the publication is to disseminate scholarly reports on the pathophysiology underlying diseases of the central and peripheral nervous system of human patients. Clinical trials that use neurophysiological measures to document change are encouraged, as are manuscripts reporting data on integrated neuroimaging of central nervous function including, but not limited to, functional MRI, MEG, EEG, PET and other neuroimaging modalities.
期刊最新文献
Polygenic mutations and their brain spatial expression contribute to presurgical evaluation in patients with refractory focal epilepsy: A case report Low-frequency EEG power and coherence differ between drug-induced parkinsonism and Parkinson’s disease Patterns of ictal surface EEG in occipital seizures: A simultaneous scalp and intracerebral recording study EEG-based responses of patients with disorders of consciousness and healthy controls to familiar and non-familiar emotional videos Effects of cervical transcutaneous spinal direct current stimulation on spinal excitability
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1